AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17532398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (1.5 mg/kg)
Number of subjects: 60
Study 17532398 — intervention group
Group type: COMPARATOR
Intervention: Saline (as control)
Number of subjects: 60
Study 15466673 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg intramuscular) every 2 weeks for 1 month
Number of subjects: 31
Study 15466673 — intervention group
Group type: COMPARATOR
Intervention: Lupron plus placebo (sesame oil as color-matched vehicle)
Number of subjects: 31
Study 15466673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron (7.5 mg intramuscularly) every 4 weeks for 3 months
Number of subjects: 31
Study 11552002 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF filtration (CSFF)
Number of subjects: 37
Study 11552002 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 37
Study 9630124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaveric donor renal transplant pathway
Number of subjects: 348
Study 9630124 — intervention group
Group type: COMPARATOR
Intervention: Living donor renal transplant pathway
Number of subjects: 348
Study 7910724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole + Sucralfate (1.0 g) administered simultaneously with 240 ml of water
Number of subjects: 12
Study 7910724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole administered 2 hours after Sucralfate (1.0 g)
Number of subjects: 12
Study 7910724 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole administered with 240 ml of water
Number of subjects: 12
Study 3582724 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone/10% urea cream
Number of subjects: 0
Study 3582724 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate cream
Number of subjects: 0
Study 30156354 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships® (PFR) program
Number of subjects: 59
Study 30156354 — intervention group
Group type: COMPARATOR
Intervention: Resource and referral control condition
Number of subjects: 59
Study 30156354 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental sensitive and responsive behavior
Number of subjects: 59
Study 29903303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (86 participants)
Number of subjects: 184
Study 29903303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (non-intenders)
Number of subjects: 184
Study 29903303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (intenders)
Number of subjects: 184
Study 29903303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (actors)
Number of subjects: 184
Study 29903303 — intervention group
Group type: COMPARATOR
Intervention: Control group (98 participants)
Number of subjects: 184
Study 25816046 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiously integrated cognitive behavioral therapy (RCBT)
Number of subjects: 132
Study 25816046 — intervention group
Group type: COMPARATOR
Intervention: Conventional cognitive behavioral therapy (CCBT)
Number of subjects: 132
Study 23078631 — intervention group
Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux (3.0 mg)
Number of subjects: 276
Study 23078631 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5 mg)
Number of subjects: 276
Study 21453509 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention (pedometer based walking programme)
Number of subjects: 0
Study 21453509 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal intervention (pedometer based walking programme)
Number of subjects: 0
Study 19422337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 192
Study 19422337 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 192
Study 16934051 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily for 4 days
Number of subjects: 9
Study 15055018 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyto-oestrogens (soya isoflavones: genistein and daidzein) for 3 months
Number of subjects: 50
Study 15055018 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 50
Study 15055018 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyto-oestrogens after placebo for 3 months
Number of subjects: 50
Study 15055018 — intervention group
Group type: COMPARATOR
Intervention: Placebo after phyto-oestrogens for 3 months
Number of subjects: 50
Study 10776362 — intervention group
Group type: EXPERIMENTAL
Intervention: Step Test Exercise Prescription (STEP)
Number of subjects: 400
Study 10776362 — intervention group
Group type: COMPARATOR
Intervention: Counseling using the American College of Sports Medicine guidelines (control)
Number of subjects: 400
Study 9176463 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous-long protocol (n = 68) with GnRH agonist administered from luteal phase until cycle day 7, followed by pure FSH administration.
Number of subjects: 92
Study 9176463 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (n = 69) with GnRH agonist administered until the day before hCG administration.
Number of subjects: 92
Study 1363221 — intervention group
Group type: EXPERIMENTAL
Intervention: F2/E2 group (fentanyl 2 micrograms.kg‐1 and esmolol 2 mg.kg‐1)
Number of subjects: 99
Study 1363221 — intervention group
Group type: EXPERIMENTAL
Intervention: F5 group (fentanyl 5 micrograms.kg‐1)
Number of subjects: 99
Study 1363221 — intervention group
Group type: COMPARATOR
Intervention: E2 group (esmolol 2 mg.kg‐1)
Number of subjects: 99
Study 1363221 — intervention group
Group type: COMPARATOR
Intervention: F2 group (fentanyl 2 micrograms.kg‐1)
Number of subjects: 99
Study 3899964 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 72
Study 3899964 — intervention group
Group type: COMPARATOR
Intervention: Control (no relaxation training)
Number of subjects: 72
Study 30804464 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone-based stepped care therapy
Number of subjects: 4736
Study 30804464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 30003628 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwegian psychomotor physiotherapy (NPMP) once weekly for 6 months
Number of subjects: 105
Study 30003628 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 105
Study 25935830 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Recovery intervention (8-session group-based intervention delivered over 5 weeks)
Number of subjects: 0
Study 25935830 — intervention group
Group type: COMPARATOR
Intervention: Control condition (treatment as usual)
Number of subjects: 0
Study 23357150 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly lipid apheresis by cascade plasma filtration (CPF) plus atorvastatin
Number of subjects: 34
Study 23357150 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone (control group)
Number of subjects: 34
Study 23357150 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly lipid apheresis by cascade plasma filtration (CPF)
Number of subjects: 34
Study 21407127 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine plus sodium bicarbonate (BASB)
Number of subjects: 20
Study 21407127 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine alone (BAMD)
Number of subjects: 20
Study 21407127 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sodium bicarbonate (PSB)
Number of subjects: 20
Study 21407127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PMD)
Number of subjects: 20
Study 19874992 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose modified-release nicotinic acid (2 g daily)
Number of subjects: 71
Study 19874992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 18210887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (hepatectomy plus radiofrequency ablation and 125I implantation)
Number of subjects: 78
Study 18210887 — intervention group
Group type: COMPARATOR
Intervention: Control group (hepatectomy alone)
Number of subjects: 78
Study 14648180 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptin (7.5 mg) combined with clomiphene citrate (150 mg on days 5-9)
Number of subjects: 100
Study 14648180 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with clomiphene citrate (150 mg on days 5-9)
Number of subjects: 100
Study 14648180 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptin (7.5 mg)
Number of subjects: 100
Study 14648180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11528493 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate‐fortified Horlicks
Number of subjects: 16
Study 11528493 — intervention group
Group type: COMPARATOR
Intervention: Calcium naturally present in milk
Number of subjects: 16
Study 8165811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. orally for 3 months in addition to oral litholysis (OLL) with ursodeoxycholic acid 500 mg/day and chenodeoxycholic acid 500 mg/day
Number of subjects: 48
Study 8165811 — intervention group
Group type: COMPARATOR
Intervention: Oral litholysis (OLL) only
Number of subjects: 48
Study 3077322 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm nitrogen dioxide (Year 1)
Number of subjects: 152
Study 3077322 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ppm nitrogen dioxide (Year 2)
Number of subjects: 152
Study 3077322 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm nitrogen dioxide (Year 3)
Number of subjects: 152
Study 3077322 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ppm nitrogen dioxide (Year 3)
Number of subjects: 152
Study 3077322 — intervention group
Group type: COMPARATOR
Intervention: Clean air (Year 1)
Number of subjects: 152
Study 3077322 — intervention group
Group type: COMPARATOR
Intervention: Clean air (Year 2)
Number of subjects: 152
Study 3077322 — intervention group
Group type: COMPARATOR
Intervention: Clean air (Year 3)
Number of subjects: 152
Study 31658460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 27
Study 31658460 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 27
Study 31658460 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 27
Study 29651862 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine
Number of subjects: 11
Study 28177671 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 7 days
Number of subjects: 30
Study 28177671 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg daily for 7 days
Number of subjects: 30
Study 26494972 — intervention group
Group type: EXPERIMENTAL
Intervention: TRE (telephone-based re-education)
Number of subjects: 140
Study 26494972 — intervention group
Group type: COMPARATOR
Intervention: Control (no TRE)
Number of subjects: 140
Study 26494972 — intervention group
Group type: EXPERIMENTAL
Intervention: TRE
Number of subjects: 140
Study 26494972 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study 23286756 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐tocopherol supplementation (50 mg/day)
Number of subjects: 29127
Study 23286756 — intervention group
Group type: COMPARATOR
Intervention: β‐carotene supplementation (20 mg/day)
Number of subjects: 29127
Study 21663925 — intervention group
Group type: EXPERIMENTAL
Intervention: 402 IU/d of vitamin D for 1 year
Number of subjects: 88
Study 21663925 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D prophylaxis
Number of subjects: 88
Study 18421801 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg s.c. scopolamine
Number of subjects: 24
Study 18421801 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg s.c. scopolamine
Number of subjects: 24
Study 18421801 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg s.c. scopolamine
Number of subjects: 24
Study 18421801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16585866 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 40
Study 16585866 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone/acetaminophen 7.5/750 mg
Number of subjects: 40
Study 12679702 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal nevirapine (NVP) therapy
Number of subjects: 1524
Study 12679702 — intervention group
Group type: COMPARATOR
Intervention: Targeted nevirapine (NVP) therapy
Number of subjects: 1524
Study 10857891 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antiemetic prophylaxis during cisplatin chemotherapy
Number of subjects: 509
Study 9296889 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. injection of heparin
Number of subjects: 12
Study 9296889 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diabetes)
Number of subjects: 12
Study 8273601 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed biopsy
Number of subjects: 570
Study 8273601 — intervention group
Group type: EXPERIMENTAL
Intervention: Random biopsy
Number of subjects: 570
Study 3304386 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 12
Study 3304386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3304386 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (in a separate open study)
Number of subjects: 12
Study 31566845 — intervention group
Group type: EXPERIMENTAL
Intervention: Decipher score
Number of subjects: 91
Study 31566845 — intervention group
Group type: EXPERIMENTAL
Intervention: RALP GGG
Number of subjects: 91
Study 31566845 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI‐lesion‐percentage
Number of subjects: 91
Study 31566845 — intervention group
Group type: EXPERIMENTAL
Intervention: Decipher+Surgery variables
Number of subjects: 91
Study 31566845 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI + Surgery variables
Number of subjects: 91
Study 31566845 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative lesion volume measured on mpMRI
Number of subjects: 91
Study 28753078 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 15
Study 28753078 — intervention group
Group type: COMPARATOR
Intervention: FCAA
Number of subjects: 15
Study 27383814 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic Prophylaxis (AP+)
Number of subjects: 74
Study 27383814 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-Coated Sutures (TCS)
Number of subjects: 74
Study 27383814 — intervention group
Group type: COMPARATOR
Intervention: Conventional Sutures (CS)
Number of subjects: 74
Study 26048976 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 24
Study 26048976 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 24158898 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen (40 mg of pantoprazole, 1 g of amoxicillin for the first 5 days, followed by 40 mg of pantoprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Number of subjects: 231
Study 24158898 — intervention group
Group type: COMPARATOR
Intervention: Standard 14-day therapy (40 mg of pantoprazole, 500 mg of clarithromycin, and 1 g of amoxicillin, each administered twice daily)
Number of subjects: 231
Study 24158898 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen
Number of subjects: 231
Study 24158898 — intervention group
Group type: COMPARATOR
Intervention: Standard 14-day therapy
Number of subjects: 231
Study 21424566 — intervention group
Group type: COMPARATOR
Intervention: Conventional bowel preparation (full cathartic dose and oral contrast medium for 3 days prior to study)
Number of subjects: 80
Study 21424566 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced bowel preparation (oral contrast medium administered only on the day of investigation)
Number of subjects: 80
Study 18376691 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched TPN (30% BCAA)
Number of subjects: 64
Study 18376691 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN (24% BCAA)
Number of subjects: 64
Study 16637077 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (n=21,210 men)
Number of subjects: 21210
Study 14644714 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable hydrogels
Number of subjects: 281
Study 14644714 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 281
Study 11004031 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflubron emulsion IV (1.2 g PFC/kg)
Number of subjects: 48
Study 11004031 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflubron emulsion IV (1.8 g PFC/kg)
Number of subjects: 48
Study 11004031 — intervention group
Group type: COMPARATOR
Intervention: Saline (3 mL/kg) control
Number of subjects: 48
Study 11004031 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflubron emulsion (both dosages)
Number of subjects: 48
Study 8400072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-assisted dosing (Group 2)
Number of subjects: 243
Study 8400072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-directed dosing (Group 3)
Number of subjects: 243
Study 8400072 — intervention group
Group type: COMPARATOR
Intervention: Usual physician‐directed dosing (Group 1)
Number of subjects: 243
Study 3536490 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol at a dose of 0.8 mg kg‐1 (Group II)
Number of subjects: 24
Study 3536490 — intervention group
Group type: COMPARATOR
Intervention: Standard anaesthesia (thiopentone, pancuronium, fentanyl and nitrous oxide) (Group I)
Number of subjects: 24
Study 29537453 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tavaborole
Number of subjects: 102
Study 29537453 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 102
Study 27177493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (75 mg, 250 mg, or 750 mg intravenously; 75 mg intravenously or 100 mg subcutaneously)
Number of subjects: 1192
Study 27177493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1192
Study 27177493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (≥150 cells per μL)
Number of subjects: 1192
Study 27177493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (≥500 cells per μL)
Number of subjects: 1192
Study 27177493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (<150 cells per μL)
Number of subjects: 1192
Study 24382064 — intervention group
Group type: COMPARATOR
Intervention: Continuing co-trimoxazole prophylaxis
Number of subjects: 758
Study 24382064 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping co-trimoxazole prophylaxis
Number of subjects: 758
Study 22305462 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 5599
Study 22305462 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (81‐324 mg per day)
Number of subjects: 5599
Study 22305462 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 5599
Study 20177766 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 254
Study 20177766 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 254
Study 20177766 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and self-management
Number of subjects: 254
Study 18319347 — intervention group
Group type: EXPERIMENTAL
Intervention: Open shoulder stabilization (n = 24)
Number of subjects: 48
Study 18319347 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic shoulder stabilization (n = 24)
Number of subjects: 48
Study 18319347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical groups (open and arthroscopic)
Number of subjects: 48
Study 15781736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (FDA-approved doses < or =0.03 microg x kg(‐1) x min(‐1))
Number of subjects: 1269
Study 15781736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (any dose up to 0.06 microg x kg(‐1) x min(‐1))
Number of subjects: 1269
Study 15781736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nesiritide (< or =0.015 microg x kg(‐1) x min(‐1))
Number of subjects: 1269
Study 15781736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (FDA-approved doses)
Number of subjects: 1269
Study 15781736 — intervention group
Group type: COMPARATOR
Intervention: Any control therapy (including non-inotrope- and inotrope-based therapies)
Number of subjects: 1269
Study 12861130 — intervention group
Group type: EXPERIMENTAL
Intervention: Presacral neurectomy (group B)
Number of subjects: 141
Study 12861130 — intervention group
Group type: COMPARATOR
Intervention: No presacral neurectomy (group A)
Number of subjects: 141
Study 10710753 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8663853 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha Fab
Number of subjects: 49
Study 8663853 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 49
Study 1800105 — intervention group
Group type: EXPERIMENTAL
Intervention: Four units of alcohol (95 ml of 40% spirit)
Number of subjects: 24
Study 1800105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6479183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (25 mg i.v.)
Number of subjects: 14
Study 6479183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (100 mg oral)
Number of subjects: 14
Study 6479183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (i.v. and orally)
Number of subjects: 14
Study 6479183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (20 mg day‐1 oral)
Number of subjects: 14
Study 6479183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31485809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-incisional nefopam (20 mg before skin incision)
Number of subjects: 150
Study 31485809 — intervention group
Group type: COMPARATOR
Intervention: Post-incisional nefopam (20 mg at 1 h after incision)
Number of subjects: 150
Study 31485809 — intervention group
Group type: COMPARATOR
Intervention: Both groups received saline at different times (Group 1: saline before incision, Group 2: saline after incision)
Number of subjects: 150
Study 29419934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (NM) at 0.5 mg/kg/h during IHD for 5 hours
Number of subjects: 18